This segment focuses on the development, manufacturing, and commercialization of biosimilars, which are highly similar versions of already-approved biologic drugs. Coherus leverages its expertise in protein engineering, analytical characterization, and clinical development to create biosimilars for high-demand therapeutic areas. The company's R&D activities include extensive preclinical studies, clinical trials, and regulatory submissions to ensure biosimilarity and efficacy. This segment addresses patient access and affordability by providing cost-effective alternatives to expensive biologics. Coherus aims to capture a significant share of the biosimilar market by offering high-quality products and competitive pricing. Future opportunities include expanding the biosimilar pipeline and entering new geographic markets. Regulatory compliance and clinical validation are critical aspects of this segment.

This segment is dedicated to the research and development of innovative immuno-oncology therapies for the treatment of cancer. Coherus is focused on developing novel antibodies and combination therapies that harness the power of the immune system to fight cancer cells. R&D activities include drug discovery, preclinical studies, and clinical trials to evaluate the safety and efficacy of new immuno-oncology candidates. The company is exploring various approaches, including checkpoint inhibitors, T-cell engagers, and oncolytic viruses, to overcome resistance mechanisms and improve patient outcomes. This segment aims to address unmet medical needs in cancer treatment by developing targeted therapies with improved efficacy and reduced toxicity. Future opportunities include expanding the immuno-oncology pipeline and forging strategic partnerships to accelerate drug development. Clinical collaborations with cancer research centers are a key component of this segment.